Arrowhead's Dual-Gene RNAi Therapy Shows Promising Early Results in Mixed Hyperlipidemia Trial — Arrowhead Pharmaceuticals, Inc.

Event summary

Arrowhead Pharmaceuticals reported interim Phase 1/2a trial data for ARO-DIMER-PA, its first dual-functional RNAi therapeutic targeting PCSK9 and APOC3 genes in mixed hyperlipidemia patients.
Single doses achieved mean maximal reductions of 54% in LDL-C, 73% in triglycerides, and 61% in non-HDL cholesterol.
The trial is ongoing to assess safety and tolerability of multiple doses, with no drug-related serious adverse events reported.
ARO-DIMER-PA is the first RNAi molecule designed to silence two genes simultaneously using Arrowhead's TRiM™ platform.

The big picture

Arrowhead's success with ARO-DIMER-PA could expand the addressable market for RNAi therapeutics in cardiometabolic diseases. The company is strategically focusing on this area, complementing its existing portfolio with REDEMPLO® and zodasiran. If proven effective, the dual-gene approach may set a new standard for treating mixed hyperlipidemia and reducing atherosclerotic cardiovascular disease risk.

What we're watching

Clinical Validation: Whether the dual-gene silencing approach will demonstrate sustained efficacy and safety in later-stage trials.
Market Positioning: How Arrowhead positions ARO-DIMER-PA against existing cardiometabolic therapies in its portfolio and competitors' offerings.
Regulatory Pathway: The pace at which Arrowhead advances ARO-DIMER-PA through clinical development and potential regulatory approval.